EMA Authorised: Rayvow (lasmiditan succinate) — Eli Lilly Nederland B.V.

View source ↗

Summary

The EMA authorised Rayvow (lasmiditan succinate) for migraine disorders; the product is manufactured by Eli Lilly Nederland B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Rayvow (lasmiditan succinate)

Snippet

Status: Authorised. Therapeutic area: Migraine Disorders. MAH: Eli Lilly Nederland B.V.. Decision date: 05/02/2026